A Phase 2 interventional study of Sintilimab Combined with Ramucirumab and Paclitaxel in Gastric Cancer (Diagnosis), sponsored by The First Affiliated Hospital with Nanjing Medical University. Not yet recruiting at 1 site in China. Open to participants aged 15 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-06-25.
Sponsored by The First Affiliated Hospital with Nanjing Medical University · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 44 studies testing sintilimab in Stomach Neoplasms — 29 open to participants now, 35 under way, 2 of them phase 3. sintilimab · Stomach Neoplasms.
Among the 44 studies testing sintilimab in Stomach Neoplasms, this one is the 30th largest by planned enrollment, is one of 7 that started in 2026, is one of 36 in phase 2, reaches primary completion later than 26 of the 34 other live ones, and was the 39th registered.
3,407 studies on the registry are indexed under Stomach Neoplasms; 994 are open to participants now.
Browse Stomach Neoplasms studies →29 of the 44 studies testing sintilimab in Stomach Neoplasms are open now, in 1 country. Recruiting first, the newest first:
Fudan University · Sites in China
Ages 18+
Fudan University · Sites in China
Ages 18–70
Zuoyi Jiao · Sites in China
Ages 18–75
Sichuan Luzhou Buchang Biopharmaceutical Co., Ltd. · Sites in China
Ages 18–75
West China Hospital · Sites in China
Ages 18–75
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 704 Stomach Neoplasms studies recruiting now, 375 (53%) set no upper age limit and 194 (28%) stop at 75 or younger; 27 take children under 18; 70 take healthy volunteers.
This study: 15 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
44 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 41 · Phase 3 4
First in 2018; this study’s year is marked. 7 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 30 is below the median of 66 across 2,505 interventional studies indexed under Stomach Neoplasms.
Median enrollment 40 across the 44 interventional studies. Of the 1 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
3 of 44 have an industry lead sponsor. The 10 most frequent:
The First Affiliated Hospital with Nanjing Medical University is the lead sponsor of 569 studies on the registry; 317 are open to participants now.
28 studies in Stomach Neoplasms by The First Affiliated Hospital with Nanjing Medical University: 21 open now, 24 under way, 2 of them phase 3. Of 1 finished, 0 (0%) have results posted.
Among the 28 studies in Stomach Neoplasms by The First Affiliated Hospital with Nanjing Medical University, this one is the 22nd largest by planned enrollment of the 23 interventional ones that give a count, is one of 7 that started in 2026, is one of 15 in phase 2, reaches primary completion later than 18 of the 23 other live ones, and was the 26th registered.
The First Affiliated Hospital with Nanjing Medical University’s Stomach Neoplasms studies by the year they started, since 2016.
4 of the studies testing sintilimab in Stomach Neoplasms that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06742411West China HospitalXELOX Combined With Sintilimab and HBO for Advanced or Metastatic GC/GEJC | 2026-12-31 |
| NCT06555471The First Affiliated Hospital with Nanjing Medical UniversityA Single-arm, Phase II Exploratory Study of Sintilimab in Combination With Chemoradiotherapy in Elderly Patients With Locally Advanced Gastric Cancer | 2026-12-31 |
| NCT07658872Sichuan UniversityPerioperative Fruquintinib Combined With Sintilimab and SOX for Locally Advanced Gastric or GEJ Adenocarcinoma | 2027-05-19 |
| NCT07669740The First Affiliated Hospital with Nanjing Medical UniversityA Study on the Efficacy and Safety of Sintilimab Combined With Ramucirumab and Paclitaxel in the Treatment of Gastric Cancer Patients With Short-term Recurrence After Adjuvant Therapy | 2027-06-01 |
Add all 4 to your calendar (.ics) → With an account.
Among the 44 studies testing sintilimab in Stomach Neoplasms, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among The First Affiliated Hospital with Nanjing Medical University’s 28 in Stomach Neoplasms:
This tab as a report to print or save as PDF → With an account.
To explore the efficacy and safety of sintilimab combined with ramucirumab and paclitaxel in the treatment of advanced gastric cancer patients with short-term recurrence after postoperative adjuvant therapy, and to identify efficacy-related biomarkers to guide subsequent individualized treatment.
The treatment of gastric cancer relies first on surgical resection. Especially for patients with early-stage and locally advanced gastric cancer, surgical resection of the tumor and regional lymph nodes constitutes the most effective therapeutic approach. The goal of surgery is to maximize survival rates and prolong patients' disease-free survival (DFS) by completely eradicating cancer cells . However, due to the high metastatic potential of gastric cancer-particularly lymph node metastasis and peritoneal metastasis-the postoperative recurrence rate remains considerable . Therefore, postoperative adjuvant therapy has become crucial for reducing recurence and improving survival outcomes.
According to the clinical guidelines of the Chinese Society of Clinical Oncology (CSCO) and the European Society for Medical Oncology (ESMO), postoperative adjuvant therapy typically adopts chemotherapy regimens, such as oxaliplatin plus S-1 (SOX), oxaliplatin plus capecitabine (CAPOX), and oxaliplatin plus 5-fluorouracil plus leucovorin (FOLFOX) . These chemotherapy regimens have achieved remarkable results by inhibiting residual micrometastatic tumor cells and reducing the risk of postoperative recurrence.
Nonetheless, despite the certain success of postoperative adjuvant therapy, some patients still experience recurrence either during adjuvant treatment or within 6 months after its completion. Once recurrence occurs, tumor treatment becomes more challenging. Such recurrence usually indicates resistance of the gastric cancer to initial therapy, and the treatment strategy post-recurrence is more complex. For patients with short-term recurrence after postoperative adjuvant therapy, the adjuvant therapy is defined as first-line treatment, and recurrence signifies progression to the second-line treatment phase.The choice of second-line treatment for this specific patient population is generally based on the patients' HER2 expression status. For HER2-positive gastric cancer patients, the trastuzumab plus chemotherapy regimen is usually administered . Multiple clinical trial results have demonstrated that trastuzumab combined with chemotherapy can significantly enhance the efficacy and survival rates of HER2-positive gastric cancer patients . For HER2-negative patients, the RAINBOW study has provided a novel therapeutic regimen of paclitaxel combined with ramucirumab for gastric cancer. The study indicated that the combination of paclitaxel and ramucirumab can significantly prolong patients' median overall survival (OS) and improve their progression-free survival (PFS). This treatment regimen has been recommended by guidelines as the standard second-line treatment option .
In recent years, the emergence of immune checkpoint inhibitors (ICIs)-especially those targeting programmed cell death protein 1 (PD-1) and programmed death-ligand 1 (PD-L1)-has brought revolutionary changes to cancer treatment. Immunotherapy activates the patients' own immune system to recognize and eliminate tumor cells, and it has exhibited significant clinical efficacy in various malignancies, including non-small cell lung cancer, melanoma, and hepatocellular carcinoma . Clinical trials such as ORIENT-16, CheckMate-649, and ATTRACTION-4 have shown that immunotherapy combined with chemotherapy can significantly improve the OS and PFS of patients with PD-L1-positive tumors.The choice of second-line treatment for this specific patient population is generally based on the patients' HER2 expression status. For HER2-positive gastric cancer patients, the trastuzumab plus chemotherapy regimen is usually administered . Multiple clinical trial results have demonstrated that trastuzumab combined with chemotherapy can significantly enhance the efficacy and survival rates of HER2-positive gastric cancer patients . For HER2-negative patients, the RAINBOW study has provided a novel therapeutic regimen of paclitaxel combined with ramucirumab for gastric cancer. The study indicated that the combination of paclitaxel and ramucirumab can significantly prolong patients' median overall survival (OS) and improve their progression-free survival (PFS). This treatment regimen has been recommended by guidelines as the standard second-line treatment option .
In recent years, the emergence of immune checkpoint inhibitors (ICIs)-especially those targeting programmed cell death protein 1 (PD-1) and programmed death-ligand 1 (PD-L1)-has brought revolutionary changes to cancer treatment. Immunotherapy activates the patients' own immune system to recognize and eliminate tumor cells, and it has exhibited significant clinical efficacy in various malignancies, including non-small cell lung cancer, melanoma, and hepatocellular carcinoma . Clinical trials such as ORIENT-16, CheckMate-649, and ATTRACTION-4 have shown that immunotherapy combined with chemotherapy can significantly improve the OS and PFS of patients with PD-L1-positive tumors
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HER2
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A Study on the Efficacy and Safety of Sintilimab Combined with Ramucirumab and Paclitaxel in the Treatment of Gastric Cancer Patients with Short-term Recurrence after Adjuvant Therapy
Drug: Sintilimab Combined with Ramucirumab and Paclitaxel
Drug pages: SintilimabStudies of SintilimabSintilimab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · RamucirumabStudies of RamucirumabRamucirumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · PaclitaxelStudies of PaclitaxelPaclitaxel pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
Sintilimab Combined with Ramucirumab and Paclitaxel in the Treatment of Gastric Cancer Patients with Short-term Recurrence after Adjuvant Therapy
Objective Response Rate (ORR)
Proportion of patients achieving complete response (CR) or partial response (PR) according to RECIST v1.1.
Time frame: From baseline until disease progression or study completion, assessed up to 24 months
Progression-Free Survival (PFS)
Progression-free survival is defined as the time from baseline to the first documented disease progression according to RECIST v1.1 or death from any cause, whichever occurs first.
Time frame: From treatment initiation until disease progression or death, whichever occurs first, assessed up to 24 months
Plan to share: Yes
Supporting information: Study protocol, Statistical analysis plan, Informed consent form
No publications or documents are linked to this record.
Start is estimated for Jul 2026; primary completion for Jun 2027, 11 months later.
Of 296 non-industry phase 2 interventional studies under Stomach Neoplasms, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 33 and three quarters within 76. This study's planned 11 months is below that.
Counting every sponsor, half of 361 studies reached it within 50 months; a quarter within 31 and three quarters within 75.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Sintilimab · Ramucirumab · Paclitaxel
The First Affiliated Hospital with Nanjing Medical University →